Artal Group S.A. cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 250,000 shares of the biopharmaceutical company’s stock after selling 25,000 shares during the quarter. Alnylam Pharmaceuticals accounts for 0.5% of Artal Group S.A.’s portfolio, making the stock its 13th biggest holding. Artal Group S.A. owned approximately 0.27% of Alnylam Pharmaceuticals worth $29,373,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 50.3% during the third quarter. Advisors Asset Management Inc. now owns 12,952 shares of the biopharmaceutical company’s stock valued at $1,522,000 after purchasing an additional 4,332 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Alnylam Pharmaceuticals by 2.4% during the third quarter. Bank of New York Mellon Corp now owns 342,105 shares of the biopharmaceutical company’s stock valued at $40,194,000 after purchasing an additional 8,163 shares in the last quarter. Rhumbline Advisers boosted its holdings in Alnylam Pharmaceuticals by 1.5% during the third quarter. Rhumbline Advisers now owns 92,568 shares of the biopharmaceutical company’s stock valued at $10,876,000 after purchasing an additional 1,346 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Alnylam Pharmaceuticals by 6.7% during the third quarter. New York State Common Retirement Fund now owns 216,488 shares of the biopharmaceutical company’s stock valued at $25,435,000 after purchasing an additional 13,500 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its holdings in Alnylam Pharmaceuticals by 42.9% during the third quarter. Candriam Luxembourg S.C.A. now owns 120,000 shares of the biopharmaceutical company’s stock valued at $14,099,000 after purchasing an additional 36,000 shares in the last quarter. 86.04% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have weighed in on ALNY shares. Goldman Sachs Group, Inc. (The) raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $62.00 to $163.00 in a report on Monday, October 2nd. Jefferies Group LLC set a $102.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 25th. B. Riley decreased their price objective on Alnylam Pharmaceuticals to $220.00 and set a “buy” rating on the stock in a report on Wednesday, November 8th. Barclays PLC lifted their price objective on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, August 10th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $99.00 price objective (down from $105.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 6th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and seventeen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $121.85.
ILLEGAL ACTIVITY WARNING: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2017/11/20/artal-group-s-a-sells-25000-shares-of-alnylam-pharmaceuticals-inc-alny.html.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the completion of the sale, the president now owns 165,399 shares in the company, valued at approximately $16,539,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Barry E. Greene sold 85,316 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 289,797 shares of company stock valued at $34,422,712 in the last quarter. Corporate insiders own 4.30% of the company’s stock.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded up $1.13 during trading on Monday, hitting $127.51. 901,000 shares of the company’s stock traded hands, compared to its average volume of 1,135,227. Alnylam Pharmaceuticals, Inc. has a 52 week low of $35.98 and a 52 week high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business’s revenue was up 24.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.21) EPS. sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -5.33 EPS for the current year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.